Stock market today: Wall Street leaps and halves its losses from what had been a dismal week
Charting, Price Performance, News & Related Contracts.
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
Scripps News on MSN23m
FDA declares shortage over for popular weight-loss, diabetes drugs
The FDA declared a shortage of popular weight-loss and diabetes drugs. Here's what that means for people who get generic ...
Novo Nordisk stock plunges 20% after a trial of its latest weight loss drug disappoints
The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...
Ozempic maker’s shares plunge after failed weight-loss trial
Shares in Novo Nordisk have fallen by more than a quarter after the Ozempic maker revealed a set of underwhelming results in ...